G6PD Deficiency: The Most Common Enzyme Deficiency Worldwide

Photo Credit: CDC/ Dr. Gilda L. Jones

Introduction

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects more than 400 million people worldwide. That makes it the most common enzyme disorder in humans. It’s also one of the most common genetic disorders overall.¹ Despite how common it is, G6PD deficiency is still underdiagnosed and poorly understood in many populations. For researchers, it offers a unique way to study oxidative stress, pharmacogenomics, and how genetic protection and disease risk can be two sides of the same coin.

The Molecular Basis: When Antioxidant Defense Fails

G6PD is the rate-limiting enzyme in the pentose phosphate pathway, the main source of NADPH in red blood cells. NADPH is essential for keeping glutathione in its reduced, protective form. This protects cells from oxidative damage. When G6PD activity is low, red blood cells become vulnerable to oxidative stress. They break down (hemolyze) when exposed to certain triggers.²

That simple explanation hides real complexity. Researchers have identified more than 200 G6PD variants, each with its own level of remaining enzyme activity, stability, and clinical impact. The WHO classification system sorts variants from Class I (severe deficiency with chronic hemolytic anemia) to Class V (increased enzyme activity). Most clinically important variants fall into Classes II and III.³

Geographic Distribution and Evolutionary Selection

G6PD deficiency shows clear geographic patterns, with the highest prevalence in:

• Sub-Saharan Africa (5–25% of males in some regions)
• Mediterranean basin (3–30% prevalence)
• Middle East and Southeast Asia (3–15%)
• Papua New Guinea and Oceania (up to 50% in some populations)

This pattern closely tracks historical malaria hotspots. It reflects positive selection for G6PD deficiency alleles, which give partial protection against severe malaria. This is a classic example of how a disease allele can persist in a population because carriers gain an advantage.⁴

For biospecimen research, this geographic and ethnic diversity means study populations need careful characterization. A G6PD-deficient person from West Africa likely carries the A- variant (G202A/A376G). This differs — with different clinical implications — from a Mediterranean patient carrying the more severe Mediterranean variant (C563T).

Clinical Manifestations: From Silent Carriers to Acute Crises

The clinical picture of G6PD deficiency ranges from a lifelong symptom-free carrier state to severe, life-threatening hemolytic crises. The outcome depends on the variant and what triggers it.

Acute Hemolytic Anemia

The most common symptom is acute hemolytic anemia, triggered by oxidative stressors:

Drug triggers:

• Antimalarials (primaquine, tafenoquine)
• Sulfonamides and sulfones (cotrimoxazole, dapsone)
• Rasburicase (used for tumor lysis syndrome)
• Certain pain relievers and fever reducers

Infections: Bacterial and viral infections can trigger hemolysis through the oxidative stress of the immune response and factors released by the pathogen.

Fava beans: Eating fava beans (favism) can cause severe acute hemolysis in people with certain variants, especially Mediterranean and some Asian variants.

Other triggers: Mothballs (naphthalene), henna, diabetic ketoacidosis.

When hemolysis happens, patients may develop sudden anemia, jaundice, dark urine, and sometimes kidney injury. Lab tests typically show low hemoglobin, high lactate dehydrogenase and indirect bilirubin, low haptoglobin, and telltale signs on a blood smear (Heinz bodies, bite cells).⁵

Neonatal Hyperbilirubinemia

G6PD deficiency is a major cause of newborn jaundice, especially in high-prevalence populations. Severe newborn jaundice can lead to kernicterus and permanent brain damage if it isn’t caught and treated quickly. Many countries with high G6PD deficiency rates now run newborn screening programs.⁶

Chronic Hemolytic Anemia

Class I variants can cause ongoing hemolytic anemia even without a specific trigger. People with severe cases may need ongoing care, including folic acid supplements, avoiding oxidative triggers, and sometimes blood transfusions.

Diagnostic Approaches: Detecting Deficiency Across the Spectrum

Diagnosing G6PD deficiency requires measuring enzyme activity directly, though screening tests and genetic analysis play a supporting role.

Enzyme Activity Assays

Quantitative spectrophotometric assay: The gold standard test measures G6PD activity under standard conditions, usually reported per gram of hemoglobin or per red blood cell. Activity below 30% of normal signals significant deficiency, though the exact cutoff varies by assay and population.

Fluorescent spot test: A quick, rough screening method that detects NADPH production under UV light. It’s useful for screening, but a positive result needs a confirmatory quantitative test.⁷

Important diagnostic considerations:

• A recent transfusion can hide a deficiency (donor red blood cells)
• A recent hemolytic episode can cause a false-negative result, since young red blood cells have higher activity
• Heterozygous females may show mixed results due to X-inactivation, which complicates diagnosis

Genetic Testing

DNA sequencing can identify specific G6PD variants, giving a definitive diagnosis that doesn’t depend on fluctuating enzyme activity levels. Genetic testing is especially useful for:

• Confirming a diagnosis in unclear cases
• Identifying specific variants for research studies
• Prenatal diagnosis in families with severe variants
• Population screening programs
• Pharmacogenomic uses (checking if malaria drugs are safe for a patient)

For biospecimen research, samples with both enzyme activity measurements and genetic variant data offer the most value. They support studies linking genotype to phenotype, and functional analysis of specific variants.

Emerging Biomarkers: Beyond Enzyme Activity

Enzyme activity measurement is still central to diagnosis. But researchers are finding additional biomarkers that may improve detection, especially of hemolysis that hasn’t caused symptoms yet.

Circulating microRNAs

A 2024 study identified circulating microRNAs — specifically miR-451a, miR-16, and miR-155 — as potential biomarkers for detecting hemolysis in G6PD deficiency before it causes symptoms. Analyzing these miRNAs together could tell G6PD-deficient people apart from healthy controls even between acute episodes. This works even when standard hemolysis tests look normal.⁸

This could mean:

• Catching hemolysis earlier, before symptoms appear
• Tracking oxidative stress across different situations
• Identifying risk in people with borderline enzyme activity
• Monitoring how well antioxidant or protective treatments work

Validating these microRNA biomarkers across different ancestries, variants, and triggers remains a research priority. This work needs well-characterized biospecimens from patients with confirmed deficiency, documented variants, and detailed symptom histories.

G6PD Activity as a Biomarker for Other Conditions

Researchers are also exploring G6PD activity as a biomarker outside of primary deficiency. Some research suggests lower G6PD activity may be linked to diabetes and higher oxidative stress. It may even track with blood sugar control.⁹ Confirming this would take comparative studies across groups with G6PD deficiency, diabetes, both, or neither.

Management and Prevention: Knowledge Enables Avoidance

There’s no cure for G6PD deficiency — management means avoiding triggers and providing supportive care during hemolytic episodes.

Primary Prevention Through Education

• Accurate diagnosis and clear communication of G6PD status
• Clear guidance on which medications to avoid
• Awareness of non-drug triggers (fava beans, naphthalene)
• Reminding patients to tell their doctor before starting new medications

Management of Acute Hemolysis

• Stop the triggering agent right away
• Provide supportive care and fluids
• Transfuse blood for severe anemia
• Watch for kidney injury linked to hemoglobin in the urine
• Give folic acid during recovery, since the body is making red blood cells faster

Public Health Interventions

• Newborn screening in high-prevalence regions
• Testing before prescribing high-risk medications (like primaquine)
• Drug-safety monitoring programs in G6PD-deficient populations
• Point-of-care diagnostic tools for resource-limited settings

Research Priorities and Opportunities

Can We Predict Hemolytic Risk More Precisely?

Not every G6PD-deficient person hemolyzes with every trigger exposure. Factors that likely play a role include:

• The specific variant and how much enzyme activity remains
• The trigger’s dose and how long the person was exposed
• Other conditions that affect oxidative stress
• Genetic modifiers in related pathways

Biospecimens from people with known trigger exposures and documented outcomes (hemolysis or no hemolysis) can support predictive biomarker development and risk modeling.

What Are the Long-Term Consequences of Subclinical Hemolysis?

Some people show signs of mild, ongoing hemolysis even without acute crises. Whether this contributes to long-term heart or other health problems is still an open question. Some early findings suggest it deserves more study.¹⁰

Can Therapeutic Interventions Reduce Oxidative Stress?

Avoiding triggers is still the main strategy. Researchers are interested in targeted interventions like antioxidant support, though no clear benefit has been proven yet.¹¹ Well-designed studies could identify which subgroups might actually benefit from these supportive treatments.

How Can We Safely Expand Access to Life-Saving Medications?

Antimalarials like primaquine and tafenoquine are important tools for eliminating malaria. But they carry a hemolysis risk for people with G6PD deficiency. Research priorities include:

• Safer dosing that reduces hemolysis
• Dosing guided by genotype or deficiency severity
• Preventive strategies that allow safe use when needed
• Alternative therapies with better safety profiles

Biospecimen Requirements for G6PD Research

Rigorous G6PD deficiency research depends on samples with thorough clinical documentation and careful handling.

Essential Clinical Documentation

Diagnostic confirmation:

• Quantitative G6PD enzyme activity measurement
• Specific genetic variant identification when available
• WHO classification (Class I–V)
• Method and timing of testing (avoid testing during acute hemolysis or shortly after a transfusion)

Symptom history:

• History of hemolytic episodes (number, triggers, severity)
• History of newborn jaundice
• Baseline hemoglobin and hemolysis markers
• Other conditions present (like diabetes or heart disease)

Ancestry and geographic origin:

• Important, since variants cluster geographically
• Supports inferring the likely variant when sequencing isn’t available

Appropriate Sample Types

Different research uses call for different sample types. For many hematology and oxidative stress studies, paired blood fractions support combined multi-omic and clinical analysis:

• Whole blood: Enzyme activity testing, DNA extraction for variant identification, and cellular assays using standard protocols. See human whole blood.
• Plasma: microRNA profiling, inflammatory marker testing, and proteomics. See human plasma (or human bulk plasma for studies needing larger volumes).
• Serum: biochemical hemolysis markers and metabolomics. See human serum.
• PBMCs: gene expression studies and cellular stress-response research. See human PBMCs.

At SanguineBio, our hematological disease biospecimens include G6PD deficiency samples with documented enzyme activity, variant characterization when available, and clinical annotation from patients across the United States. These patients represent diverse ancestries and geographic origins.

Global Health Implications

G6PD deficiency sits at the crossroads of genetics, pharmacology, infectious disease, and global health. Because it’s common in malaria-endemic regions, it complicates malaria elimination efforts that rely on drugs with hemolytic risk. As a pharmacogenomic factor, it shapes medication safety across many treatment areas. And as an example of balanced selection, it offers insight into evolutionary medicine and how hosts and pathogens interact.

For global health researchers, it’s essential to design studies that account for variant diversity and different risk levels. Biospecimen collections supporting this work need samples from populations that are often underrepresented in biomedical research, despite carrying the highest disease burden.

Conclusion

G6PD deficiency shows how a single enzyme defect can lead to wildly different outcomes — from a silent carrier state to life-threatening hemolysis. The outcome depends on the genetic variant, environmental exposures, and other patient factors. As the most common enzyme disorder worldwide, it affects hundreds of millions of people and touches major public health programs, from malaria control to newborn care.

Research opportunities include validating new biomarkers like circulating microRNAs, understanding the consequences of subclinical hemolysis, and developing safer access to essential medications. There’s also a need to understand how genetic protection against malaria shapes disease risk today. Progress depends on access to well-characterized biospecimens from diverse populations with confirmed diagnoses and thorough clinical and molecular annotation.

Explore our G6PD deficiency biospecimens or request a custom collection for global health or pharmacogenomics research.

---

References (AMA Style)

1. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267-278. doi:10.1016/j.bcmd.2008.12.005
2. Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30(2):373-393. doi:10.1016/j.hoc.2015.11.006
3. World Health Organization Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67(6):601-611.
4. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74. doi:10.1016/S0140-6736(08)60073-2
5. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005;72(7):1277-1282.
6. Mohamed GS, Lemine SM, Cheibetta S, Mohamed A. Neonatal screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency in Mauritania. Pan Afr Med J. 2018;30:224. doi:10.11604/pamj.2018.30.224.15805
7. Roper D, Layton M, Rees D, et al. Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. Br J Haematol. 2020;189(1):24-38. doi:10.1111/bjh.16366
8. Jittikoon J, Sanpakit K, Buaban A, et al. Serum microRNAs as new biomarkers for detecting subclinical hemolysis in G6PD deficiency. Sci Rep. 2024;14(1):16547. doi:10.1038/s41598-024-67394-8
9. Wan GH, Tsai SC, Chiu DT. Decreased blood activity of glucose-6-phosphate dehydrogenase associates with increased risk for diabetes mellitus. Endocrine. 2002;19(2):191-195. doi:10.1385/ENDO:19:2:191
10. Chonat S, Quarmyne MO. Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency. Pediatr Ann. 2020;49(3):e135-e141. doi:10.3928/19382359-20200214-01
11. Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med. 1954;44(2):171-176.